Efficacy and safety of valsartan 160mg/hydrochlorothiazide 25mg combination in patients with hypertension not adequately controlled by valsartan 160mg/hydrochlorothiazide 12.5mg

Clinical Drug Investigation

Volumn 24, Issue 10, 2004, Pages 593-602

  Trenkwalder, Peter ^a,c   Ulmer, Hans Joachim ^b   Weidinger, Gottfried ^c   Handrock, Renate ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Novartis Pharma ^*

^c Klinikum Starnberg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCHLOROTHIAZIDE; VALSARTAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFICACY; DRUG MIXTURE; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HUMAN; HYPERTENSION; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

EID: 21344471995     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200424100-00005     Document Type: Article

References (27)

1. Guidelines subcommittee. World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83
2. Dickerson J, Hingorani A, Ashby M, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008-13
3. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-62
4. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-72
5. Guidelines Committee. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53
6. Deutsche Liga zur Bekämpfung des hohen Blutdruckes e.V., Deutsche Hochdruckliga [German Hypertension League]. Guidelines for the prevention, detection, diagnostics and therapy of hypertension [in German]. Bonn, 2003
7. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of HIgh Blood Pressure. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413-46
8. Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299-311
9. Benz JR, Black HR, Graff A, et al. Valsartan and hydrochlorothiazide in patients with essential hypertension: a multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy. J Hum Hypertens 1998; 12: 861-6
10. Schmidt A, Adam SA, Kolloch R, et al. Antihypertensive effects of valsartan/hydrochlorothiazide combination in essential hypertension. Blood Press 2001; 10: 230-7
11. Palatini P, Malacco E, Fogari R, et al. A multicenter, randomized double-blind study of valsartan/hydrochlorothiazide combination versus amlodipine in patients with mild to moderate hypertension. J Hypertens 2001; 19: 1691-6
12. Waeber B, Aschwanden R, Sadecky L, et al. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. J Hypertens 2001; 19: 2097-104
13. Julius S, Kjeldsen SE, Weber M, et al. VALUE trial: outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31
14. Hall J, Marbury T, Gray J. Long-term safety, tolerability and efficacy of valsartan: results from one and two year trials. J Drug Assess 1998; 1: 281-93
15. Chrysant S, Wombolt D, Feliciano N, et al. Long-term efficacy, safety, and tolerability of valsartan and hydrochlorothiazide in patients with essential hypertension. Curr Ther Res 1998; 59: 762-72
16. Perloff D, Grim C, Flack J, et al. Human blood pressure determination by sphygmomanometry. Circulation 1993; 88: 2460-70
17. American Society of Hypertension. Recommendations for routine blood pressure measurement by indirect cuff sphygmomanometry. Am J Hypertens 1992; 5: 207-9
18. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease: pt 2. Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38
19. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000; 356: 1955-64
20. Mallion JM, Carretta R, Trenkwalder P, et al. Valsartan/ hydrochlorothiazide is effective in hypertensive patients inadequately controlled by valsartan monotherapy. Blood Pressure Suppl 2003; Suppl. 1: 36-43
21. Wellington K, Faulds DM. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension. Drugs 2002; 62: 1983-2005
22. Myers M. Compliance in hypertension: why don't patients take their pills? CMAJ 1999; 160: 64-5
23. Holzgreve H, Middeke M. Risk-benefit aspects of antihypertensive drugs. Drugs 1992; 44 Suppl. 1: 67-73
24. Gress TW, Nieto FJ, Shahar E, et al. The Atherosclerosis Risk in Communities Study: hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 2000; 342: 905-12
25. Lindholm L, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study. J Hypertens 2002; 20: 1879-86
26. Grossman E, Messerli FH, Goldbourt U. High blood pressure and diabetes mellitus: are all antihypertensive drugs created equal? Arch Intern Med 2000; 160: 2447-52
27. American Diabetes Association. Treatment of hypertension in adults with diabetes: position statement. Diabetes Care 2003; 26: 80S-2S